Hit enter to search or ESC to close
Expansion Therapeutics
  • Home
  • About
    • Company Overview
    • Our Partners
    • Leadership Team
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Pipeline of Compositions
    • Expansion Repeat Disorders
    • Myotonic Dystrophy Type 1
    • Myotonic Dystrophy Type 2
  • Platform
    • Overview
    • Publications
  • Newsroom
  • Contact
    • General Inquiries
    • Partnership Inquiries
    • Career Opportunities
    • News Alerts

Newsroom

Expansion News and Insights

Media Contact

Christy Curran
Sam Brown Inc.
(615) 414-8668
christycurran@sambrown.com

News Alerts

Subscribe to Receive News Alerts

Small Molecule Silences Cancer-driving RNA, Opens Up Previously Undruggable Targets – FierceBiotech

Novel RNA-Modifying Tool Corrects Genetic Diseases, Including Driver of Triple-negative Breast Cancer – TSRI

Expanding Small Molecule Horizons – BioCentury

Press Release

Expansion Therapeutics Raises $55.3 Million in Series A Financing to Advance Portfolio of Novel RNA Targeted Small Molecule Medicines to Treat Rare Diseases

Names Kevin M. Forrest, Ph.D. President and CEO Proprietary technology based on pioneering work from…
Expansion Therapeutics
Expansion TherapeuticsJanuary 3, 2018

Small Molecules Against RNA Targets Attract Big Backers – Nature Reviews Drug Discovery

The RNA Drug Hunters – Chemical and Engineering News

Bringing RNA into the Fold: Small Molecules Find New Targets in RNA to Combat Disease – Nature Medicine

Precise Small-Molecule Recognition of a Toxic CUG RNA Repeat Expansion – Nature Chemical Biology

Scripps Team Develops New Platform Tech for RNA-defect Diseases – FierceBiotech

Scripps Florida Awarded $2.5M to Advance Development of RNA-Based Therapeutics – TSRI

« Previous 1 2 3 Next »

© 2021 Expansion Therapeutics | Terms of Use | Privacy Policy

  • Home
  • About
    • Company Overview
    • Our Partners
    • Leadership Team
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Pipeline of Compositions
    • Expansion Repeat Disorders
    • Myotonic Dystrophy Type 1
    • Myotonic Dystrophy Type 2
  • Platform
    • Overview
    • Publications
  • Newsroom
  • Contact
    • General Inquiries
    • Partnership Inquiries
    • Career Opportunities
    • News Alerts

Recent News and Insights

  • Expansion Therapeutics Names Renato Skerlj, Ph.D., Chief Executive Officer and President October 5, 2020
  • Expansion Therapeutics Expands Leadership Team with Two Key Appointments; Names World-Renowned Scientist Lynne E. Maquat, Ph.D., to its Scientific Advisory Board June 17, 2019
  • Scientists Take Aim at Disease-Causing RNAs Using Small-Molecule Drugs – The Scientist April 1, 2019